Edward Mostone, DPM
Primary Podiatric Medicine · Medford, MANPI 1043208242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Stryker at 39.7% of the total. Reporting peaked in 2019 at $303 and has fallen 90.0% since, to $30 in 2023.
Across 24 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$241
- Smith+Nephew$169
- Hikma Pharmaceuticals USA$52
- Amgen$43
- Merck$33
- Orthofix Medical, Inc.$26
- plus $43 from 2 others
What the payments were for
- Food & beverage$606100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker(2 entities) | 8 | $241 |
| Smith+Nephew | 4 | $169 |
| Hikma Pharmaceuticals USA | 3 | $52 |
| Amgen | 3 | $43 |
| Merck | 2 | $33 |
| Orthofix Medical, Inc. | 2 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Grafix PL PRIME$139
- Stravix$139
How this compares
Too few primary podiatric medicine providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluconazole | 78 | $746 |
| Gabapentin | 35 | $335 |
| Ketoconazole | 15 | $327 |
| Allopurinol | 17 | $170 |
| Cephalexin | 25 | $144 |
| Azithromycin | 20 | $123 |
| Ibuprofen | 18 | $60 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Medford
- Anthony TicknerHudson$284K
- David AlperBelmont$4K
- Jeffrey ResnickHarvard$2K
- Katherine KootMilford$1K
- Richard GenoveseGardner$1K
- Robert UhrichBoston$1K
- Dominick GaribaldiWinthrop$681
- Paul HeffernanCambridge$321
- Frank MoleWilbraham$229
- Jack DalyMalden$169
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.